Total Funding
23
41
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
222205
Oasmia Pharmaceutical develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology.
Margareta Eriksson: Vice President Clinical Development
Hans Sundin: Executive Vice President
About the Company
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product
development is based on in-house research within nanotechnology and company patents.
